Seer, Inc.
SEERAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 4, 2026 | Canaccord Genuity | Kyle Mikson | $4.00(+97%) | $2.03 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Morgan Stanley | maintain | Equal Weight | Aug 13, 2024 |
| Morgan Stanley | maintain | Equal Weight | Feb 21, 2023 |
| B of A Securities | downgrade | Neutral →Underperform | Jan 4, 2023 |
| Morgan Stanley | maintain | Equal Weight | Nov 10, 2022 |
| JP Morgan | downgrade | Overweight →Neutral | Aug 11, 2022 |
| Morgan Stanley | maintain | Equal Weight | Aug 11, 2022 |
| Morgan Stanley | maintain | Equal Weight | May 5, 2022 |
| Morgan Stanley | maintain | Equal Weight | Mar 1, 2022 |
| Morgan Stanley | maintain | Equal Weight | Feb 15, 2022 |
| Morgan Stanley | maintain | Equal Weight | Aug 13, 2021 |
| Morgan Stanley | maintain | Equal Weight | May 12, 2021 |
| Morgan Stanley | maintain | Equal Weight | Mar 30, 2021 |
| JP Morgan | maintain | Overweight | Dec 29, 2020 |
| Cowen & Co. | maintain | Outperform | Dec 29, 2020 |
| Morgan Stanley | maintain | Equal Weight | Dec 29, 2020 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.31 | $-0.27 | $3.1M | $3.5M |
| May 13, 2026 | $-0.30 | $-0.29 | $2.8M | $3.6M |
| Feb 26, 2026 | $-0.29 | $-0.32 | $4.2M | $4.6M |
| Nov 6, 2025 | $-0.32 | $-0.32 | $4.1M | $4.6M |
| Aug 6, 2025 | $-0.33 | $-0.39 | $4.1M | $3.8M |
| May 13, 2025 | $-0.34 | $-0.37 | $4.2M | $4.0M |
| Feb 27, 2025 | $-0.34 | $-0.31 | $3.9M | $4.0M |
| Nov 6, 2024 | $-0.34 | $-0.29 | $3.9M | $4.0M |
News
REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced a significant victory in its patent enforcement action against Nanomics Biotechnology Co., Ltd.
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter. *** November 2, 2026 Fellow Stockholders and Members of the Board of Directors (the “Board”), On October 29, 2026, Seer announced that its two-member Special Committee had rejected the separate acquisition proposals submitted by us and by Chairman and CEO Omid Farokhzad, M.
REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer's Board of Directors (the “Special Committee”) has concluded its review process and decided to reject the recent acquisition proposals made to Seer.
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecif
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2026 on Tuesday, November 10, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Convention & Exhibition Centre.
REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company's President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company.
Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population health Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population…
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani. *** September 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Meeta Gulyani Dear Ms. Gulyani, As you know, we are significant stockholders of Seer, Inc. (“Seer” or the “Company”), collectively owning approximately 7.7% of the Company's.
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today issued the following open letter to the Company's Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Board of Directors Dear Members of the Board of Directors (the “Board”), Bradley L. Radoff and Michael Torok (together with certain of their affiliat.
Seer NASDAQ: SEER reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers.
Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript
REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended June 30, 2026.